美国NovaBios
疟疾(pf)检测试剂盒(HRP-2/PLDH)
广州健仑生物科技有限公司
本公司为大家供应各种进口品Pai疟疾(疟原虫)检测试剂盒,包括美国的NovaBios、美国CORTEZ、美国BinaxNOW、韩国SD、广州创仑等美国CDC指定品Pai。主要包括胶体金、酶免、PCR等方法学。欢迎咨询
非洲等热带国家工作用疟疾(疟原虫)检测试纸
泰国等热带疫情发生国家旅游用疟疾(疟原虫)检测试纸
恶性疟原虫、间日疟原虫、三日疟原虫、卵形疟原虫检测试剂盒
进口疟疾检测卡、疟原虫检测试剂盒、疟疾抗原检测试剂盒
美国NovaBios疟疾(pf)检测试剂盒(HRP-2/PLDH)
以青高素为基础的联合疗法含有青高素和搭配药物。近年来,在大湄公河次区域5个国家(柬埔寨,老挝人民民主共和国,缅甸,泰国,越南)中发现,疟原虫对青高素产生了耐药性。研究结果证实,在该地区许多地方,独自出现了青高素耐药性。
2013年,世卫组织在大湄公河次区域发起了紧急应对青高素耐药性行动。这是一项高级别计划,目的是遏制耐药寄生虫的传播,并为面临疟疾风险的所有人群提供救命工具。但即使在开展这项工作期间,在大湄公河次区域的一些新的地区仍独自出现了青高素耐药性现象。还有报道称,在有些地方,对联合疗法搭配药物的耐药性有所增加。因此,需要根据疟疾的不断演变情况采用新的处理方法。
因此,世卫组织疟疾政策咨询委员会于2014年9月建议制定一项关于到2030年在大湄公河次区域消除恶性疟的目标。世卫组织在2015年5月发起了大湄公河次区域消除疟疾战略(2015-2030年),该战略获得该地区所有国家的支持。在世卫组织的技术指导下,大湄公河次区域各国制定了国家消除疟疾计划。世卫组织将与各合作伙伴一道,在紧急应对青高素耐药性计划的基础上,开展一项新的消除疟疾计划,持续支持该地区各国开展消除疟疾工作。
监测
监测系指追踪疾病和规划应对措施并根据所获信息采取行动。目前,许多疟疾高负担国家的监测系统较弱,无法评估疾病分布和相关趋势,所以很难优化应对措施和处理疫情。
美国NovaBios疟疾(pf)检测试剂盒(HRP-2/PLDH)
The combination of aconitin-based combination therapy contains cyanogens and medications. In recent years, malaria parasites have been resistant to cyanogens in five countries (Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, and Vietnam) in the Greater Mekong Subregion. The results confirmed that in many parts of the region, alone appeared in the green high resistance.
In 2013, WHO launched an emergency response to high-sensitivity drug resistance in the Greater Mekong Subregion. This is a high-level program aimed at curbing the spread of drug-resistant parasites and providing life-saving tools for all people at risk for malaria. However, even during the course of this work, there was a new phenomenon in the new areas of the Greater Mekong Subregion. It has also been reported that in some places, the resistance to combination therapy has increased. Therefore, new treatments are required based on the evolving situation of malaria.
Therefore, the WHO Malaria Policy Advisory Committee proposed in September 2014 the development of a target for the elimination of falciparum malaria in the Greater Mekong Subregion by 2030. In May 2015, WHO launched the Greater Mekong Subregion Malaria Elimination Strategy (2015-2030), which was supported by all countries in the region. Under the technical guidance of WHO, the countries of the Greater Mekong Subregion have developed a national malaria eradication program. WHO will work with partners to develop a new malaria eradication program on the basis of an emergency response to the program, which will continue to support the efforts of the countries of the region to eradicate malaria.
monitor
Monitoring refers to tracking disease and planning response and taking action based on the information obtained. At present, many malaria-borne countries have weak monitoring systems and can not assess disease distribution and related trends, making it difficult to optimize responses and address the epidemic.
美国NovaBios
我司还提供其它进口或国产试剂盒:登革热、疟疾、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
想了解更多的NovaBios产品及服务请扫描下方二维码:
【公司名称】 广州健仑生物科技有限公司
【市场部】 杨永汉
【】
【腾讯 】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室